Cell and gene therapy makers met in Rome to discuss the field's outlook in Europe. One main topic of conversation: the FDA.
The view over Rome, the site of the Alliance for Regenerative Medicine’s recent Meeting on the Med.Dan Kitwood/Getty Images
By Andrew Joseph
May 6, 2026
Europe Correspondent
Andrew Joseph
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
Pierre Fabre claims to now be “aligned” with U.S. regulators on the path forward for a twice-rejected treatment. Elsewhere,…
Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and…
Strengthening core CDO values for cell line development | Strengthening core CDO values for cell line development
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
